Navigation Links
Study Suggests a Possible Way to Offset Chemobrain Memory Loss
Date:9/5/2008

MORGANTOWN, W.Va., Sept. 5 /PRNewswire-USNewswire/ -- Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University, researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce.

In the WVU researchers' study, published in the September issue of the journal Metabolic Brain Disease, rats were given the commonly used chemotherapy drugs adriamycin and cyclophosphamide. When on the drugs, rats trained to prefer a light room to a dark room forgot their training.

"When animals are treated with chemotherapy drugs, they lose memory," said Gregory Konat, Ph.D., professor of neurobiology and anatomy at WVU. "When we add NAC during treatment, they don't lose memory."

Chosen for its antioxidant properties, NAC is a modified form of the dietary amino acid cysteine.

Jame Abraham, M.D., director of the Comprehensive Breast Cancer Program at WVU's Mary Babb Randolph Cancer Center, said as "chemobrain" entered the national lexicon, many patients expressed frustration about doctors not taking the complaints seriously.

"In the past, there was a lot of ignorance among doctors about chemo-induced cognitive problems," Dr. Abraham said. "In some patients, problems can persist for up to two years."

The WVU authors say as many as 40 percent of cancer patients undergoing chemotherapy complain of symptoms such as severe memory and attention deficits. Previously, scientists suspected the cancer, rather than chemo drugs, might be the cause.

Earlier this year, Dr. Abraham's team of researchers used MRI scans to document the extent of changes to the brain in women who received chemotherapy for breast cancer. Now the connection between drugs and memory loss is clear, and a potential remedy is suggested as well.

"At this point, we have no evidence to say that NAC is safe in patients who are getting chemotherapy," Abraham said. "We need more studies to confirm the role of NAC in patients."

In addition to the Department of Neurobiology and Anatomy, researchers from WVU's Mary Babb Randolph Cancer Center and Department of Behavioral Medicine and Psychiatry collaborated on the study.

The study was funded as part of a $275,000 grant over three years from the U.S. Department of Defense. Abraham is principle investigator on the studies.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE West Virginia University Health Sciences Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytopia Commences Second Phase II Study in Brain Cancer
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. CDC Misses Target With Flawed MMR/Autism Study
5. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
6. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
8. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
9. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
Breaking Medicine News(10 mins):